MDS risk scores

MDS risk scores are standardised scoring systems used to estimate prognosis and guide treatment decisions for people with myelodysplastic syndromes, a group of blood disorders affecting the bone marrow's ability to produce healthy blood cells. They combine various factors including blood counts, bone marrow findings, and specific genetic changes to categorise risk.

Common factors include the severity of low blood counts, the percentage of abnormal cells in the bone marrow, and specific chromosomal or genetic abnormalities found in the cancer cells. These combined factors help place each person into a specific risk category with associated prognosis information.

They help guide treatment decisions, since lower-risk MDS is often managed with less intensive supportive treatment, while higher-risk MDS may need more active treatment, including potentially intensive chemotherapy or stem cell transplant, depending on individual circumstances and fitness. They also give patients and families important prognostic information to guide decision-making.

No, risk scores are calculated individually based on each person's specific blood test results, bone marrow findings, and genetic testing results, meaning two people with an MDS diagnosis can have quite different risk categories and, therefore, different recommended treatment approaches. This individualised assessment is central to modern MDS management.

Yes, since MDS can evolve, sometimes progressing to a higher-risk category or, in some cases, to acute myeloid leukaemia, risk scores may be recalculated at different points during the disease course, particularly if there's a change in blood counts or symptoms. Regular monitoring helps track this potential evolution.

They're calculated using established international scoring systems that combine blood count severity, the percentage of abnormal cells in bone marrow samples, and specific genetic and chromosomal test results into a composite risk category. Your haematologist will explain your specific score and what it means for your individual treatment planning.

Lower-risk categories often guide towards supportive care approaches focused on managing symptoms and blood counts, while higher-risk categories may prompt consideration of more intensive treatments including specific medications, chemotherapy, or stem cell transplant in suitable candidates. Your specific score, alongside your overall fitness and preferences, shapes this individualised treatment discussion.

Lower-risk MDS is often managed with supportive care such as blood transfusions and medications to support blood counts, aiming to maintain quality of life, while higher-risk MDS more often warrants consideration of active disease-modifying treatment given a greater risk of complications or progression. This distinction, guided by the calculated risk score, significantly shapes the overall treatment strategy and monitoring intensity.

This depends on individual circumstances, but reassessment is often considered if there's a significant change in blood counts, symptoms, or at specific decision points regarding treatment, such as when considering more intensive options like transplant. Your haematology team will advise on an appropriate schedule for your specific situation.

If you've been diagnosed with MDS, discussing your specific risk score and its implications with a haematologist is an important part of understanding your prognosis and treatment options. Private haematology consultations can typically be arranged within about two weeks, considerably faster than standard NHS waiting times.